Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer

Oncogene

Volumn 27, Issue 21, 2008, Pages 3021-3031

  Al Azawi, D ^a,b   Ilroy, M M ^a   Kelly, G ^b   Redmond, A M ^a   Bane, F T ^a   Cocchiglia, S ^a   Hill, A D K ^a   Young, L S ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast cancer; Ets 2; Myc; SRC 1; Tamoxifen resistance

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P160; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 2;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RESISTANCE; CELL STRAIN MCF 7; DISEASE FREE SURVIVAL; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; NUCLEAR PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS C-MYC; TAMOXIFEN;

EID: 43449106199     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210964     Document Type: Article

References (27)

1. Bronzert DA, Greene GL, Lippman ME. (1985). Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 117: 1409-1417.
2. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R. (1993). Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53: 283-290.
3. Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. (2004). Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 32: 4358-4367.
4. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. (1993). Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223-228.
5. Cosgrave N, Hill ADK, Young LS. (2006). Growthfactor-dependent regulation of surviving by c-myc in human breast cancer. J Mol Endocrinol 37: 377-390.
6. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T et al. (2006). Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumours: a mechanism of tamoxifen resistance. Cancer Res 66: 5950-5959.
7. Duke RC, Witter RZ, Nash PB, Young JD, Ojcius DM. (1994). Cytolysis mediated by ionophores and pore-forming agents: role of intracellular calcium in apoptosis. FASEB J 8: 237-246.
8. Elston CW, Ellis IO. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
9. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ. (2004). Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 24: 10954-10964.
10. Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM et al. (1998). Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signalling. Mol Cell Biol 18: 5148-5156.
11. Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN et al. (1996). Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J Biol Chem 271: 7992-7998.
12. Goel A, Janknecht R. (2004). Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 279: 14909-14916.
13. Grandori C, Cowley SM, James LP, Eisenman RN. (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699.
14. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE et al. (2003). Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81: 81-93.
15. Jayaraman G, Srinivas R, Duggan C, Ferreira E, Swaminathan S, Somasundaram K et al. (1999). p300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoter. J Biol Chem 274: 17342-17352.
16. McIlroy M, Fleming FJ, Buggy Y, Hill ADK, Young LS. (2006). Tamoxifen induced ER-alpha - SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer 13: 1135-1145.
17. McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC et al. (2006). c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol 102: 147-155.
18. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y et al. (2005). Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 11: 2111-2122.
19. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N et al. (2004). Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10: 346S-354S.
20. Osborne CK, Shou J, Massarweh S, Schiff R. (2005). Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865s-870s.
21. Papoutsopoulou S, Janknecht R. (2000). Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol 20: 7300-7310.
22. Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW. (1994). Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene 9: 405-415.
23. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514.
24. Sharrocks AD, Brown AL, Ling Y, Yates PR. (1997). The ETS-domain transcription factor family. Int J Biochem Cell Biol 29: 1371-1387.
25. Shepherd T, Hassell JA. (2001). Role of Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 6: 129-140.
26. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, Stacey KJ et al. (1996). Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 16: 538-547.
27. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK. (1998). A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol 18: 2218-2229.